Rifaximin (BioDeep_00000397483)

   

natural product Chemicals and Drugs


代谢物信息卡片


[(9E,19E)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.14,7.05,35.026,34.027,32]heptatriaconta-1(35),2,4,9,19,21,25(36),26(34),28,30,32-undecaen-13-yl] acetate

化学式: C43H51N3O11 (785.3523416)
中文名称: 利福昔明
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C
InChI: InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)

描述信息

A semisynthetic rifamycin derivative and non-systemic gastrointestinal site-specific broad spectrum antibiotic. Used in the treatment of travellers diarrhea, hepatic encephalopathy and irritable bowel syndrome.
A - Alimentary tract and metabolism > A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents > A07A - Intestinal antiinfectives > A07AA - Antibiotics
D - Dermatologicals > D06 - Antibiotics and chemotherapeutics for dermatological use > D06A - Antibiotics for topical use
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D012294 - Rifamycins
C254 - Anti-Infective Agent > C258 - Antibiotic
D005765 - Gastrointestinal Agents
CONFIDENCE standard compound; INTERNAL_ID 1179
CONFIDENCE standard compound; EAWAG_UCHEM_ID 3693
INTERNAL_ID 1179; CONFIDENCE standard compound

同义名列表

3 个代谢物同义名

Rifaximin; [(9E,19E)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.14,7.05,35.026,34.027,32]heptatriaconta-1(35),2,4,9,19,21,25(36),26(34),28,30,32-undecaen-13-yl] acetate; Rifaximin (Xifaxan)



数据库引用编号

37 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Qi Yuan, Yuan Fang, Jingyun Guo, Zheng Zhang, Jinmao Liao, Jia Kuang. Therapeutic potential and mechanisms of Rifaximin in ameliorating iron overload-induced ferroptosis and liver fibrosis in vivo and in vitro. Toxicology and applied pharmacology. 2024 Mar; 484(?):116845. doi: 10.1016/j.taap.2024.116845. [PMID: 38331104]
  • Darshan Mehta, Miao Li, Noriko Nakamura, Mani Chidambaram, Xiaobo He, Matthew S Bryant, Ralph Patton, Kelly Davis, Jeffrey Fisher. In vivo pharmacokinetic analyses of placental transfer of three drugs of different physicochemical properties in pregnant rats. Reproductive toxicology (Elmsford, N.Y.). 2022 08; 111(?):194-203. doi: 10.1016/j.reprotox.2022.06.007. [PMID: 35714934]
  • Bálint Baráth, Dávid K Jász, Tamara Horváth, Bence Baráth, Gergely Maróti, Gerda Strifler, Gabriella Varga, Lilla Sándor, Domonkos Perényi, Szabolcs Tallósy, Tibor Donka, Péter Jávor, Mihály Boros, Petra Hartmann. Mitochondrial Side Effects of Surgical Prophylactic Antibiotics Ceftriaxone and Rifaximin Lead to Bowel Mucosal Damage. International journal of molecular sciences. 2022 May; 23(9):. doi: 10.3390/ijms23095064. [PMID: 35563455]
  • Elisa Pose, Elsa Solà, Juan J Lozano, Adrià Juanola, Julia Sidorova, Giacomo Zaccherini, Koos de Wit, Frank Uschner, Marta Tonon, Konstantin Kazankov, Cesar Jiménez, Daniela Campion, Laura Napoleone, Ann T Ma, Marta Carol, Manuel Morales-Ruiz, Carlo Alessandria, Ulrich Beuers, Paolo Caraceni, Claire Francoz, François Durand, Rajeshwar P Mookerjee, Jonel Trebicka, Victor Vargas, Salvatore Piano, Hugh Watson, Juan G Abraldes, Patrick S Kamath, Mark M Davis, Pere Ginès. Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. Hepatology communications. 2022 05; 6(5):1100-1112. doi: 10.1002/hep4.1881. [PMID: 34964311]
  • Ji Won Han, Da In Kim, Hee Chul Nam, U Im Chang, Jin Mo Yang, Do Seon Song. Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis. Clinical and molecular hepatology. 2022 04; 28(2):219-231. doi: 10.3350/cmh.2021.0082. [PMID: 34281295]
  • Xin Wen, Cong Shen, Jinyu Xia, Lan-Lan Zhong, Zhongwen Wu, Mohamed Abd El-Gawad El-Sayed Ahmed, Nana Long, Furong Ma, Guili Zhang, Wenwei Wu, Jianlve Luo, Yong Xia, Min Dai, Liyan Zhang, Kang Liao, Siyuan Feng, Cha Chen, Yishen Chen, Wenji Luo, Guo-Bao Tian. Whole-Genome Sequencing Reveals the High Nosocomial Transmission and Antimicrobial Resistance of Clostridioides difficile in a Single Center in China, a Four-Year Retrospective Study. Microbiology spectrum. 2022 02; 10(1):e0132221. doi: 10.1128/spectrum.01322-21. [PMID: 35019676]
  • Vishal C Patel, Sunjae Lee, Mark J W McPhail, Kevin Da Silva, Susie Guilly, Ane Zamalloa, Elizabeth Witherden, Sidsel Støy, Godhev Kumar Manakkat Vijay, Nicolas Pons, Nathalie Galleron, Xaiohong Huang, Selin Gencer, Muireann Coen, Thomas Henry Tranah, Julia Alexis Wendon, Kenneth D Bruce, Emmanuelle Le Chatelier, Stanislav Dusko Ehrlich, Lindsey Ann Edwards, Saeed Shoaie, Debbie Lindsay Shawcross. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. Journal of hepatology. 2022 02; 76(2):332-342. doi: 10.1016/j.jhep.2021.09.010. [PMID: 34571050]
  • Prashant Singh, Eric J Alm, John M Kelley, Vivian Cheng, Mark Smith, Zain Kassam, Judy Nee, Johanna Iturrino, Anthony Lembo. Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D. Gut microbes. 2022 Jan; 14(1):2020067. doi: 10.1080/19490976.2021.2020067. [PMID: 35014601]
  • Nina Kimer, Mads Meldgaard, Ole Hamberg, Thit Mynster Kronborg, Allan M Lund, Holger Jon Møller, Flemming Bendtsen, Henriette Ytting. The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial. PloS one. 2022; 17(3):e0264278. doi: 10.1371/journal.pone.0264278. [PMID: 35286322]
  • Yuki Fujimoto, Kosuke Kaji, Norihisa Nishimura, Masahide Enomoto, Koji Murata, Soichi Takeda, Hiroaki Takaya, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji. Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity. World journal of gastroenterology. 2021 Dec; 27(48):8323-8342. doi: 10.3748/wjg.v27.i48.8323. [PMID: 35068872]
  • Junxiong Cheng, Yafang Chen, Wenfu Cao, Guoqing Zuo. Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis. Medicine. 2021 Dec; 100(51):e28232. doi: 10.1097/md.0000000000028232. [PMID: 34941089]
  • Khadija A M Glal, Sherief M Abd-Elsalam, Tarek M Mostafa. Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial. Journal of hepato-biliary-pancreatic sciences. 2021 Oct; 28(10):812-824. doi: 10.1002/jhbp.947. [PMID: 33768619]
  • Amirhossein Shamsaddini, Patrick M Gillevet, Chathur Acharya, Andrew Fagan, Edith Gavis, Masoumeh Sikaroodi, Sara McGeorge, Alexander Khoruts, Somaya Albhaisi, Michael Fuchs, Richard K Sterling, Jasmohan S Bajaj. Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis. Gastroenterology. 2021 08; 161(2):508-521.e7. doi: 10.1053/j.gastro.2021.04.013. [PMID: 33857456]
  • Jasmohan S Bajaj, Masoumeh Sikaroodi, Amirhossein Shamsaddini, Zachariah Henseler, Tasha Santiago-Rodriguez, Chathur Acharya, Andrew Fagan, Phillip B Hylemon, Michael Fuchs, Edith Gavis, Tonya Ward, Dan Knights, Patrick M Gillevet. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. Gut. 2021 06; 70(6):1162-1173. doi: 10.1136/gutjnl-2020-322470. [PMID: 32998876]
  • Chang Hu, Vikram Anjur, Krishnakant Saboo, K Rajender Reddy, Jacqueline O'Leary, Puneeta Tandon, Florence Wong, Guadalupe Garcia-Tsao, Patrick S Kamath, Jennifer C Lai, Scott W Biggins, Michael B Fallon, Paul Thuluvath, Ram M Subramanian, Benedict Maliakkal, Hugo Vargas, Leroy R Thacker, Ravishankar K Iyer, Jasmohan S Bajaj. Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis. The American journal of gastroenterology. 2021 02; 116(2):336-346. doi: 10.14309/ajg.0000000000000971. [PMID: 33038139]
  • Cristina Tocia, Irina Magdalena Dumitru, Luana Alexandrescu, Lucian Cristian Petcu, Eugen Dumitru. Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?. Medicine. 2021 Jan; 100(1):e24059. doi: 10.1097/md.0000000000024059. [PMID: 33429768]
  • Brian E Lacy, Mark Pimentel, Darren M Brenner, William D Chey, Laurie A Keefer, Millie D Long, Baha Moshiree. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. The American journal of gastroenterology. 2021 01; 116(1):17-44. doi: 10.14309/ajg.0000000000001036. [PMID: 33315591]
  • Cassandra Kimber, Shiqin Zhang, Cassandra Johnson, Raymond E West, Alexander J Prokopienko, Jonathan D Mahnken, Alan S Yu, Andrew N Hoofnagle, Diana Ir, Charles E Robertson, Makoto Miyazaki, Michel Chonchol, Anna Jovanovich, Bryan Kestenbaum, Daniel N Frank, Thomas D Nolin, Jason R Stubbs. Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD. Kidney360. 2020 Nov; 1(11):1206-1216. doi: 10.34067/kid.0003942020. [PMID: 34322673]
  • Ying Li, Gaichao Hong, Min Yang, Gangping Li, Yu Jin, Hanhua Xiong, Wei Qian, Xiaohua Hou. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome. Pharmacological research. 2020 09; 159(?):104936. doi: 10.1016/j.phrs.2020.104936. [PMID: 32470562]
  • Dibyendu Dutta, Kelvin Li, Barbara Methe, Seah H Lim. Rifaximin on intestinally-related pathologic changes in sickle cell disease. American journal of hematology. 2020 04; 95(4):E83-E86. doi: 10.1002/ajh.25722. [PMID: 31925798]
  • Dániel Kuti, Zsuzsanna Winkler, Krisztina Horváth, Balázs Juhász, Melinda Paholcsek, Anikó Stágel, Gabriella Gulyás, Levente Czeglédi, Szilamér Ferenczi, Krisztina J Kovács. Gastrointestinal (non-systemic) antibiotic rifaximin differentially affects chronic stress-induced changes in colon microbiome and gut permeability without effect on behavior. Brain, behavior, and immunity. 2020 02; 84(?):218-228. doi: 10.1016/j.bbi.2019.12.004. [PMID: 31821847]
  • Xin-Yue Lv, Hui-Guo Ding, Jun-Fu Zheng, Chun-Lei Fan, Lei Li. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study. World journal of gastroenterology. 2020 Jan; 26(2):199-218. doi: 10.3748/wjg.v26.i2.199. [PMID: 31988585]
  • Magnhild E Macpherson, Johannes R Hov, Thor Ueland, Tuva B Dahl, Martin Kummen, Kari Otterdal, Kristian Holm, Rolf K Berge, Tom E Mollnes, Marius Trøseid, Bente Halvorsen, Pål Aukrust, Børre Fevang, Silje F Jørgensen. Gut Microbiota-Dependent Trimethylamine N-Oxide Associates With Inflammation in Common Variable Immunodeficiency. Frontiers in immunology. 2020; 11(?):574500. doi: 10.3389/fimmu.2020.574500. [PMID: 33042155]
  • Tomasz Banasiewicz, Jacek Paszkowski, Maciej Borejsza-Wysocki, Adam Bobkiewicz, Anna Pietrzak, Marek Szczepkowski, Wojciech Francuzik. Efficacy of combined prophylactic therapy (rifaximine alpha + prebiotic arabinogalactan with lactofferin) on GUT function in patients with diagnosed symptomatic uncomplicated diverticular disease. Polski przeglad chirurgiczny. 2019 Aug; 91(4):1-8. doi: 10.5604/01.3001.0013.4115. [PMID: 31481638]
  • Manuele Furnari, Alessandra De Alessandri, Federico Cresta, Maria Haupt, Marta Bassi, Angela Calvi, Riccardo Haupt, Giorgia Bodini, Iftikhar Ahmed, Francesca Bagnasco, Edoardo Giovanni Giannini, Rosaria Casciaro. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. Journal of gastroenterology. 2019 Mar; 54(3):261-270. doi: 10.1007/s00535-018-1509-4. [PMID: 30232597]
  • S F Jørgensen, M E Macpherson, T Bjørnetrø, K Holm, M Kummen, A Rashidi, A E Michelsen, T Lekva, B Halvorsen, M Trøseid, T E Mollnes, R K Berge, A Yndestad, T Ueland, T H Karlsen, P Aukrust, J R Hov, B Fevang. Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency. Scientific reports. 2019 01; 9(1):167. doi: 10.1038/s41598-018-35367-7. [PMID: 30655568]
  • Darja Gramec Skledar, Adriana Carino, Jurij Trontelj, Johanna Troberg, Eleonora Distrutti, Silvia Marchianò, Tihomir Tomašič, Anamarija Zega, Moshe Finel, Stefano Fiorucci, Lucija Peterlin Mašič. Endocrine activities and adipogenic effects of bisphenol AF and its main metabolite. Chemosphere. 2019 Jan; 215(?):870-880. doi: 10.1016/j.chemosphere.2018.10.129. [PMID: 30408883]
  • Anthony A Fodor, Mark Pimentel, William D Chey, Anthony Lembo, Pamela L Golden, Robert J Israel, Ian M Carroll. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut microbes. 2019; 10(1):22-33. doi: 10.1080/19490976.2018.1460013. [PMID: 29708822]
  • Christian Schulz, Kerstin Schütte, Ramiro Vilchez-Vargas, Riccardo Vasapolli, Peter Malfertheiner. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy. Digestive diseases (Basel, Switzerland). 2019; 37(2):161-169. doi: 10.1159/000494216. [PMID: 30428474]
  • Seok-Hoon Lee, Cho-Rong Kim, Kyu-Nam Kim. Changes in Fecal Calprotectin After Rifaximin Treatment in Patients With Nonconstipated Irritable Bowel Syndrome. The American journal of the medical sciences. 2019 01; 357(1):23-28. doi: 10.1016/j.amjms.2018.11.004. [PMID: 30611316]
  • L Laghi, P Mastromarino, W Elisei, D Capobianco, C L Zhu, M Picchio, G Giorgetti, G Brandimarte, A Tursi. Impact of treatments on fecal microbiota and fecal metabolome in symptomatic uncomplicated diverticular disease of the colon: a pilot study. Journal of biological regulators and homeostatic agents. 2018 Nov; 32(5):1421-1432. doi: . [PMID: 30574746]
  • Xiao-Jun Cai, Lei Wang, Chun-Mei Hu. Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta-analysis involving 826 patients based on 10 randomized controlled trials. Journal of cellular biochemistry. 2018 11; 119(10):8336-8345. doi: 10.1002/jcb.26886. [PMID: 29932239]
  • Ahmed Abdel-Razik, Nasser Mousa, Walaa Shabana, Mohamed Refaey, Rasha Elzehery, Rania Elhelaly, Khaled Zalata, Mostafa Abdelsalam, Ahmed A Eldeeb, Mahmoud Awad, Ayman Elgamal, Ahmed Attia, Niveen El-Wakeel, Waleed Eldars. Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot. European journal of gastroenterology & hepatology. 2018 10; 30(10):1237-1246. doi: 10.1097/meg.0000000000001232. [PMID: 30096092]
  • Uday C Ghoshal, Deepakshi Srivastava, Asha Misra. A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology. 2018 Sep; 37(5):416-423. doi: 10.1007/s12664-018-0901-6. [PMID: 30406392]
  • Mohamed A Mekky, Ahmad R Riad, Marwa A Gaber, Mohamed O Abdel-Malek, Yosef M Swifee. Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: An open labeled randomized clinical trial. Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology. 2018 Jun; 19(2):76-79. doi: 10.1016/j.ajg.2018.06.001. [PMID: 29935863]
  • Bradley Reuter, Kara Walter, Julien Bissonnette, Michael D Leise, Jennifer Lai, Puneeta Tandon, Patrick S Kamath, Scott W Biggins, Christopher F Rose, James B Wade, Jasmohan S Bajaj. Assessment of the spectrum of hepatic encephalopathy: A multicenter study. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2018 05; 24(5):587-594. doi: 10.1002/lt.25032. [PMID: 29457869]
  • S W Zhu, Z J Liu, M Li, H Q Zhu, L P Duan. [Comparison of gut microbiotal compositional analysis of patients with irritable bowel syndrome through different bioinformatics pipelines]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences. 2018 Apr; 50(2):231-238. doi: NULL. [PMID: 29643520]
  • Edford Sinkala, Kanekwa Zyambo, Ellen Besa, Patrick Kaonga, Bright Nsokolo, Violet Kayamba, Michael Vinikoor, Rabison Zulu, Martin Bwalya, Graham R Foster, Paul Kelly. Rifaximin Reduces Markers of Inflammation and Bacterial 16S rRNA in Zambian Adults with Hepatosplenic Schistosomiasis: A Randomized Control Trial. The American journal of tropical medicine and hygiene. 2018 04; 98(4):1152-1158. doi: 10.4269/ajtmh.17-0637. [PMID: 29436337]
  • Bjørn Stæhr Madsen, Jonel Trebicka, Maja Thiele, Mads Israelsen, Manimozhiyan Arumugan, Troels Havelund, Aleksander Krag. Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial. Trials. 2018 Feb; 19(1):143. doi: 10.1186/s13063-018-2523-9. [PMID: 29482588]
  • Nina Kimer, Natasja Stæhr Gudmann, Julie Steen Pedersen, Søren Møller, Mette Juul Nielsen, Diana Julie Leeming, Morten Asser Karsdal, Holger Jon Møller, Flemming Bendtsen, Henning Grønbæk. No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial. PloS one. 2018; 13(9):e0203200. doi: 10.1371/journal.pone.0203200. [PMID: 30183743]
  • Nina Kimer, Julie S Pedersen, Juliette Tavenier, Jeffrey E Christensen, Troels M Busk, Lise Hobolth, Aleksander Krag, Waleed Abu Al-Soud, Martin S Mortensen, Søren J Sørensen, Søren Møller, Flemming Bendtsen. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. Journal of gastroenterology and hepatology. 2018 Jan; 33(1):307-314. doi: 10.1111/jgh.13852. [PMID: 28671712]
  • Francesco Drago, Giulia Ciccarese, Eleonora Indemini, Vincenzo Savarino, Aurora Parodi. Psoriasis and small intestine bacterial overgrowth. International journal of dermatology. 2018 01; 57(1):112-113. doi: 10.1111/ijd.13797. [PMID: 29057460]
  • Kosuke Kaji, Hiroaki Takaya, Soichiro Saikawa, Masanori Furukawa, Shinya Sato, Hideto Kawaratani, Mitsuteru Kitade, Kei Moriya, Tadashi Namisaki, Takemi Akahane, Akira Mitoro, Hitoshi Yoshiji. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World journal of gastroenterology. 2017 Dec; 23(47):8355-8366. doi: 10.3748/wjg.v23.i47.8355. [PMID: 29307995]
  • Agnieszka Gawronska, Marcin Banasiuk, Dominika Lachowicz, Hanna Pituch, Piotr Albrecht, Aleksandra Banaszkiewicz. Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial. Inflammatory bowel diseases. 2017 12; 23(12):2209-2214. doi: 10.1097/mib.0000000000001249. [PMID: 29084080]
  • Seung Kak Shin, Oh Sang Kwon, Jong Joon Lee, Yeon Ho Park, Cheol Soo Choi, Sung Hwan Jeong, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim. Effect of Rifaximin on Hepatic Fibrosis in Bile Duct-ligated Rat Model. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi. 2017 Nov; 70(5):239-246. doi: 10.4166/kjg.2017.70.5.239. [PMID: 29161793]
  • El-Sayed Ibrahim, Ayman Alsebaey, Hassan Zaghla, Sabry Moawad Abdelmageed, Khalid Gameel, Eman Abdelsameea. Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome. European journal of gastroenterology & hepatology. 2017 Nov; 29(11):1247-1250. doi: 10.1097/meg.0000000000000967. [PMID: 28902040]
  • M Pimentel, B D Cash, A Lembo, R A Wolf, R J Israel, P Schoenfeld. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. Digestive diseases and sciences. 2017 09; 62(9):2455-2463. doi: 10.1007/s10620-017-4598-7. [PMID: 28589238]
  • Kiran Ahire, Archana Sonawale. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy. The Journal of the Association of Physicians of India. 2017 Aug; 65(8):42-46. doi: NULL. [PMID: 28799305]
  • Michael Camilleri, Guy Boeckxstaens. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017 05; 66(5):966-974. doi: 10.1136/gutjnl-2016-313425. [PMID: 28232472]
  • Nina Kimer, Julie Steen Pedersen, Troels Malte Busk, Lise Lotte Gluud, Lise Hobolth, Aleksander Krag, Søren Møller, Flemming Bendtsen. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. Hepatology (Baltimore, Md.). 2017 02; 65(2):592-603. doi: 10.1002/hep.28898. [PMID: 27775818]
  • Wolfgang Stremmel, Kathrin V Schmidt, Vera Schuhmann, Frank Kratzer, Sven F Garbade, Claus-Dieter Langhans, Gert Fricker, Jürgen G Okun. Blood Trimethylamine-N-Oxide Originates from Microbiota Mediated Breakdown of Phosphatidylcholine and Absorption from Small Intestine. PloS one. 2017; 12(1):e0170742. doi: 10.1371/journal.pone.0170742. [PMID: 28129384]
  • James H Tabibian, Andrea Gossard, Mounif El-Youssef, John E Eaton, Jan Petz, Roberta Jorgensen, Felicity B Enders, Anilga Tabibian, Keith D Lindor. Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. American journal of therapeutics. 2017 Jan; 24(1):e56-e63. doi: 10.1097/mjt.0000000000000102. [PMID: 24914504]
  • Amr S Hanafy, Ahmad M Hassaneen. Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival. European journal of gastroenterology & hepatology. 2016 Dec; 28(12):1455-1461. doi: 10.1097/meg.0000000000000743. [PMID: 27622998]
  • Tien Dong, Andrew Aronsohn, K Gautham Reddy, Helen S Te. Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis. Digestive diseases and sciences. 2016 12; 61(12):3621-3626. doi: 10.1007/s10620-016-4313-0. [PMID: 27655104]
  • Alam García-Heredia, Santos García, José Ángel Merino-Mascorro, Peter Feng, Norma Heredia. Natural plant products inhibits growth and alters the swarming motility, biofilm formation, and expression of virulence genes in enteroaggregative and enterohemorrhagic Escherichia coli. Food microbiology. 2016 Oct; 59(?):124-32. doi: 10.1016/j.fm.2016.06.001. [PMID: 27375253]
  • Natalia Zeber-Lubecka, Maria Kulecka, Filip Ambrozkiewicz, Agnieszka Paziewska, Krzysztof Goryca, Jakub Karczmarski, Tymon Rubel, Wojciech Wojtowicz, Piotr Mlynarz, Lukasz Marczak, Roman Tomecki, Michal Mikula, Jerzy Ostrowski. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. Gut microbes. 2016 09; 7(5):397-413. doi: 10.1080/19490976.2016.1215805. [PMID: 27662586]
  • M Assem, M Elsabaawy, M Abdelrashed, S Elemam, S Khodeer, W Hamed, A Abdelaziz, G El-Azab. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. Hepatology international. 2016 Mar; 10(2):377-85. doi: 10.1007/s12072-015-9688-z. [PMID: 26660707]
  • Matteo Fornai, Luca Antonioli, Carolina Pellegrini, Rocchina Colucci, Deborah Sacco, Erika Tirotta, Gianfranco Natale, Alessia Bartalucci, Marina Flaibani, Cecilia Renzulli, Emilia Ghelardi, Corrado Blandizzi, Carmelo Scarpignato. Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. Pharmacological research. 2016 Feb; 104(?):186-96. doi: 10.1016/j.phrs.2015.12.031. [PMID: 26747402]
  • J S Bajaj. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Alimentary pharmacology & therapeutics. 2016 Jan; 43 Suppl 1(?):11-26. doi: 10.1111/apt.13435. [PMID: 26618922]
  • M Pimentel. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Alimentary pharmacology & therapeutics. 2016 Jan; 43 Suppl 1(?):37-49. doi: 10.1111/apt.13437. [PMID: 26618924]
  • Xin Zeng, Xia Jiao Tang, Xia Sheng, Wu Ni, Hai Guang Xin, Wei Zhong Chen, Cai Feng Jiang, Yong Lin, Jian Shi, Bin Shi, Yue Xiang Chen, Zong Li Yuan, Wei Fen Xie. Does low-dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study. Journal of digestive diseases. 2015 Nov; 16(11):665-74. doi: 10.1111/1751-2980.12294. [PMID: 26474237]
  • Heather M Mascio, Christie A Joya, Richard A Plasse, Thomas P Baker, Michael F Flessner, Robert Nee. An unusual cause of acute kidney injury due to oxalate nephropathy in systemic scleroderma. Clinical nephrology. 2015 Aug; 84(2):111-5. doi: 10.5414/cn108406. [PMID: 25500295]
  • Naiara Orrego-Lagarón, Miriam Martínez-Huélamo, Anna Vallverdú-Queralt, Rosa M Lamuela-Raventos, Elvira Escribano-Ferrer. High gastrointestinal permeability and local metabolism of naringenin: influence of antibiotic treatment on absorption and metabolism. The British journal of nutrition. 2015 Jul; 114(2):169-80. doi: 10.1017/s0007114515001671. [PMID: 26083965]
  • Venkatanarayana Gangarapu, Ali Tüzün Ince, Birol Baysal, Yusuf Kayar, Ulkan Kılıç, Özlem Gök, Ömer Uysal, Hakan Şenturk. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. European journal of gastroenterology & hepatology. 2015 Jul; 27(7):840-5. doi: 10.1097/meg.0000000000000348. [PMID: 26043290]
  • Tarek Mostafa, Gamal Badra, Mahmoud Abdallah. The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology. 2015 Mar; 26(2):163-9. doi: 10.5152/tjg.2015.7782. [PMID: 25835116]
  • Corrado Blandizzi, Giuseppe Claudio Viscomi, Carmelo Scarpignato. Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers. Drug design, development and therapy. 2015; 9(?):1-11. doi: 10.2147/dddt.s72572. [PMID: 25565769]
  • Jennifer M Colquhoun, Rachel A F Wozniak, Paul M Dunman. Clinically Relevant Growth Conditions Alter Acinetobacter baumannii Antibiotic Susceptibility and Promote Identification of Novel Antibacterial Agents. PloS one. 2015; 10(11):e0143033. doi: 10.1371/journal.pone.0143033. [PMID: 26558753]
  • Ali A Wahib, M Negm El-Deen Salem, Mostafa A Ahmed, Yasser M M El-Dessouky, Diaa M El-Tiby, Khaled El-Mola, Abeer M El-Sayed. Evaluation of rifaximin in management of hepatic encephalopathy. Journal of the Egyptian Society of Parasitology. 2014 Dec; 44(3):677-85. doi: 10.12816/0007871. [PMID: 25643509]
  • Valérie Martel-Laferrière, Caitlin Homberger, Kian Bichoupan, Douglas T Dieterich. MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy. BMC gastroenterology. 2014 Oct; 14(?):185. doi: 10.1186/1471-230x-14-185. [PMID: 25326084]
  • Corrado Blandizzi, Giuseppe Claudio Viscomi, Antonio Marzo, Carmelo Scarpignato. Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. Pharmacological research. 2014 Jul; 85(?):39-44. doi: 10.1016/j.phrs.2014.05.001. [PMID: 24836868]
  • Alfonso Fasano, Francesco Bove, Maurizio Gabrielli, Enzo Ragazzoni, Serena Fortuna, Annalisa Tortora, Maria Assunta Zocco, Stefano Marconi, Antonio Gasbarrini, Anna Rita Bentivoglio. Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth. Clinical neuropharmacology. 2014 Jul; 37(4):91-5. doi: 10.1097/wnf.0000000000000034. [PMID: 24992085]
  • Valentina Sepe, Claudio D'Amore, Raffella Ummarino, Barbara Renga, Maria Valeria D'Auria, Ettore Novellino, Annamaria Sinisi, Orazio Taglialatela-Scafati, Yoichi Nakao, Vittorio Limongelli, Angela Zampella, Stefano Fiorucci. Insights on pregnane-X-receptor modulation. Natural and semisynthetic steroids from Theonella marine sponges. European journal of medicinal chemistry. 2014 Feb; 73(?):126-34. doi: 10.1016/j.ejmech.2013.12.005. [PMID: 24388834]
  • Lisa N Patel, Jason Schairer, Bo Shen. Fecal transplantation therapy for Clostridium difficile-associated pouchitis. International journal of colorectal disease. 2014 Feb; 29(2):263-4. doi: 10.1007/s00384-013-1771-0. [PMID: 24132529]
  • Mi-Sung Kim, Walter Morales, Andres Ardila Hani, Sharon Kim, Gene Kim, Stacy Weitsman, Christopher Chang, Mark Pimentel. The effect of rifaximin on gut flora and Staphylococcus resistance. Digestive diseases and sciences. 2013 Jun; 58(6):1676-82. doi: 10.1007/s10620-013-2675-0. [PMID: 23589147]
  • Aneesh S Patel, Elisa M Supan, Shereef N Ali. Toxic epidermal necrolysis associated with rifaximin. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013 May; 70(10):874-6. doi: 10.2146/ajhp120137. [PMID: 23640348]
  • Muna Qayed, Amelia Langston, Kuang-Yueh Chiang, Keith August, Joseph A Hilinski, Conrad R Cole, Andre Rogatko, Roberd M Bostick, John T Horan. Rifaximin for preventing acute graft-versus-host disease: impact on plasma markers of inflammation and T-cell activation. Journal of pediatric hematology/oncology. 2013 May; 35(4):e149-52. doi: 10.1097/mph.0b013e31827e56af. [PMID: 23274384]
  • Genta Kakiyama, William M Pandak, Patrick M Gillevet, Phillip B Hylemon, Douglas M Heuman, Kalyani Daita, Hajime Takei, Akina Muto, Hiroshi Nittono, Jason M Ridlon, Melanie B White, Nicole A Noble, Pamela Monteith, Michael Fuchs, Leroy R Thacker, Masoumeh Sikaroodi, Jasmohan S Bajaj. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. Journal of hepatology. 2013 May; 58(5):949-55. doi: 10.1016/j.jhep.2013.01.003. [PMID: 23333527]
  • Guy W Neff, Michael Jones, Mark Jonas, Ravi Ravinuthala, David Novick, Tiffany E Kaiser, Nyingi Kemmer. Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysis. Journal of clinical gastroenterology. 2013 Feb; 47(2):188-92. doi: 10.1097/mcg.0b013e318276be13. [PMID: 23314671]
  • Jasmohan S Bajaj, Douglas M Heuman, Arun J Sanyal, Phillip B Hylemon, Richard K Sterling, R Todd Stravitz, Michael Fuchs, Jason M Ridlon, Kalyani Daita, Pamela Monteith, Nicole A Noble, Melanie B White, Andmorgan Fisher, Masoumeh Sikaroodi, Huzefa Rangwala, Patrick M Gillevet. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PloS one. 2013; 8(4):e60042. doi: 10.1371/journal.pone.0060042. [PMID: 23565181]
  • Jie Cheng, Kristopher W Krausz, Naoki Tanaka, Frank J Gonzalez. Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice. Toxicological sciences : an official journal of the Society of Toxicology. 2012 Oct; 129(2):456-68. doi: 10.1093/toxsci/kfs211. [PMID: 22790967]
  • Mohamad A Hanouneh, Ibrahim A Hanouneh, Jana G Hashash, Ryan Law, Jamak Modaresi Esfeh, Rocio Lopez, Nyla Hazratjee, Thomas Smith, Nizar N Zein. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. Journal of clinical gastroenterology. 2012 Sep; 46(8):709-15. doi: 10.1097/mcg.0b013e3182506dbb. [PMID: 22878533]
  • Ramisetti Nageswara Rao, Rajavarapu Mastan Vali, Alamanda Vara Prasada Rao. Determination of rifaximin in rat serum by ionic liquid based dispersive liquid-liquid microextraction combined with RP-HPLC. Journal of separation science. 2012 Aug; 35(15):1945-52. doi: 10.1002/jssc.201200202. [PMID: 22753340]
  • Georgios N Kalambokis, Athanasia Mouzaki, Maria Rodi, Konstantinos Pappas, Andreas Fotopoulos, Xanthi Xourgia, Epameinondas V Tsianos. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2012 Jul; 10(7):815-8. doi: 10.1016/j.cgh.2012.02.025. [PMID: 22391344]
  • Gemma Odena, Mireia Miquel, Anna Serafín, Amparo Galan, Rosa Morillas, Ramon Planas, Ramon Bartolí. Rifaximin, but not growth factor 1, reduces brain edema in cirrhotic rats. World journal of gastroenterology. 2012 May; 18(17):2084-91. doi: 10.3748/wjg.v18.i17.2084. [PMID: 22563196]
  • Georgios N Kalambokis, Athanasia Mouzaki, Maria Rodi, Epameinondas V Tsianos. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia. Liver international : official journal of the International Association for the Study of the Liver. 2012 Mar; 32(3):467-75. doi: 10.1111/j.1478-3231.2011.02650.x. [PMID: 22098272]
  • Karim M Eltawil, Marie Laryea, Kevork Peltekian, Michele Molinari. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World journal of gastroenterology. 2012 Feb; 18(8):767-77. doi: 10.3748/wjg.v18.i8.767. [PMID: 22371636]
  • Barbara Renga, Andrea Mencarelli, Claudio D'Amore, Sabrina Cipriani, Maria Valeria D'Auria, Valentina Sepe, Maria Giovanna Chini, Maria Chiara Monti, Giuseppe Bifulco, Angela Zampella, Stefano Fiorucci. Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PloS one. 2012; 7(1):e30443. doi: 10.1371/journal.pone.0030443. [PMID: 22291955]
  • Jasmohan S Bajaj, Jason M Ridlon, Phillip B Hylemon, Leroy R Thacker, Douglas M Heuman, Sean Smith, Masoumeh Sikaroodi, Patrick M Gillevet. Linkage of gut microbiome with cognition in hepatic encephalopathy. American journal of physiology. Gastrointestinal and liver physiology. 2012 Jan; 302(1):G168-75. doi: 10.1152/ajpgi.00190.2011. [PMID: 21940902]
  • Mark Pimentel, Walter Morales, Sam-Ryong Jee, Kimberly Low, Laura Hwang, Venkata Pokkunuri, Jim Mirocha, Jeffrey Conklin, Christopher Chang. Antibiotic prophylaxis prevents the development of a post-infectious phenotype in a new rat model of post-infectious IBS. Digestive diseases and sciences. 2011 Jul; 56(7):1962-6. doi: 10.1007/s10620-010-1548-z. [PMID: 21222158]
  • A G Evdokimova, A É Radzevich, A V Tomova, V V Evdokimov, E V Kovalenko, L V Zhukolenko. [Optimization of treatment of patients with chronic cardiac insufficiency of the ischemic genesis and hobnail liver]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]. 2011; 56(5-6):64-8. doi: NULL. [PMID: 22145233]
  • Simone Maccaferri, Beatrice Vitali, Annett Klinder, Sofia Kolida, Maurice Ndagijimana, Luca Laghi, Fiorella Calanni, Patrizia Brigidi, Glenn R Gibson, Adele Costabile. Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. The Journal of antimicrobial chemotherapy. 2010 Dec; 65(12):2556-65. doi: 10.1093/jac/dkq345. [PMID: 20852272]
  • M Furnari, A Parodi, L Gemignani, E G Giannini, S Marenco, E Savarino, L Assandri, V Fazio, D Bonfanti, S Inferrera, V Savarino. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Alimentary pharmacology & therapeutics. 2010 Oct; 32(8):1000-6. doi: 10.1111/j.1365-2036.2010.04436.x. [PMID: 20937045]
  • R Nageswara Rao, R Mastan Vali, Dhananjay D Shinde. On-line 2D-LC-ESI/MS/MS determination of rifaximin in rat serum. Biomedical chromatography : BMC. 2009 Nov; 23(11):1145-50. doi: 10.1002/bmc.1236. [PMID: 19444797]
  • Indi Trehan, Robert J Shulman, Ching-Nan Ou, Kenneth Maleta, Mark J Manary. A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy. The American journal of gastroenterology. 2009 Sep; 104(9):2326-33. doi: 10.1038/ajg.2009.270. [PMID: 19491826]
  • R Nageswara Rao, Dhananjay D Shinde, Sachin B Agawane. Rapid determination of rifaximin in rat serum and urine by direct injection on to a shielded hydrophobic stationary phase by HPLC. Biomedical chromatography : BMC. 2009 Jun; 23(6):563-7. doi: 10.1002/bmc.1149. [PMID: 19101925]
  • J Vlachogiannakos, A S Saveriadis, N Viazis, I Theodoropoulos, K Foudoulis, S Manolakopoulos, S Raptis, D G Karamanolis. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Alimentary pharmacology & therapeutics. 2009 May; 29(9):992-9. doi: 10.1111/j.1365-2036.2009.03958.x. [PMID: 19210289]
  • Antonio Tursi, Giovanni Brandimarte, Walter Elisei, Gian Marco Giorgetti, Cosimo Damiano Inchingolo, Fabio Aiello. Faecal calprotectin in colonic diverticular disease: a case-control study. International journal of colorectal disease. 2009 Jan; 24(1):49-55. doi: 10.1007/s00384-008-0595-9. [PMID: 18941760]
  • S M Finegold, D Molitoris, M-L Väisänen. Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Antimicrobial agents and chemotherapy. 2009 Jan; 53(1):281-6. doi: 10.1128/aac.00441-08. [PMID: 18955526]
  • NULL. [Bacterially induced traveler's diarrhea. Local antibiosis effective without systemic effects]. MMW Fortschritte der Medizin. 2008 Nov; 150(45):48-9. doi: NULL. [PMID: 19058391]